Should I buy or sell InspireMD stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InspireMD in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NSPR shares. View NSPR analyst ratings or view top-rated stocks .

What is InspireMD's stock price target for 2024?

1 Wall Street analysts have issued 12-month price objectives for InspireMD's stock. Their NSPR share price targets range from $4.50 to $5.20. On average, they predict the company's stock price to reach $4.85 in the next year. This suggests a possible upside of 132.1% from the stock's current price. View analysts price targets for NSPR or view top-rated stocks among Wall Street analysts .

How have NSPR shares performed in 2024?

InspireMD's stock was trading at $2.81 at the start of the year. Since then, NSPR shares have decreased by 25.6% and is now trading at $2.09. View the best growth stocks for 2024 here .

When is InspireMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our NSPR earnings forecast .

How were InspireMD's earnings last quarter?

InspireMD, Inc. (NYSE:NSPR) posted its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. The company earned $1.76 million during the quarter, compared to analyst estimates of $1.65 million. InspireMD had a negative net margin of 320.97% and a negative trailing twelve-month return on equity of 55.71%. During the same quarter in the prior year, the business earned ($0.60) EPS.

What other stocks do shareholders of InspireMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InspireMD investors own include Akorn (AKRXQ) , Akers Biosciences (AKER) , Akebia Therapeutics (AKBA) , Adamis Pharmaceuticals (ADMP) , ADMA Biologics (ADMA) , Acasti Pharma (ACST) , AcelRx Pharmaceuticals (ACRX) , Acorda Therapeutics (ACOR) , Aurora Cannabis (ACB) and Ambev (ABEV) .

How do I buy shares of InspireMD?

Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:NSPR

InspireMD (NSPR) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free NSPR Stock Alerts

$2.09

-0.05 (-2.34%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.07
▼
$2.15
50-Day Range: $2.09
▼
$2.79
52-Week Range: $0.96
▼
$3.85

Volume: 15,876 shs
Average Volume: 68,653 shs
Market Capitalization: $49.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.85

Get InspireMD alerts:

InspireMD MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 132.1% Upside
$4.85 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.61) to ($0.50) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.01 out of 5 stars

Medical Sector

573rd out of 911 stocks

Surgical & Medical Instruments Industry

64th out of 98 stocks

3.5

Analyst's Opinion

Consensus Rating
InspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
InspireMD has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for NSPR.

0.0

Dividend Strength

Dividend Yield
InspireMD does not currently pay a dividend.
Dividend Growth
InspireMD does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NSPR.

2.0

News and Social Media Coverage

News Sentiment
InspireMD has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for InspireMD this week, compared to 0 articles on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, InspireMD insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.62% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for InspireMD are expected to grow in the coming year, from ($0.61) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of InspireMD is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of InspireMD is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
InspireMD has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About InspireMD Stock (NYSE:NSPR)

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

NSPR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NSPR Stock News Headlines

April 16, 2024 | americanbankingnews.com

InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

April 3, 2024 | finance.yahoo.com

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 20, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 3, 2024 | globenewswire.com

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 31, 2024 | msn.com

Pope Francis appeals for Gaza cease-fire and Russia-Ukraine prisoner swap in Easter Sunday prayers

March 26, 2024 | globenewswire.com

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

March 6, 2024 | finanznachrichten.de

InspireMD, Inc.: InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 6, 2024 | investorplace.com

NSPR Stock Earnings: InspireMD Beats EPS, Beats Revenue for Q4 2023

April 20, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 6, 2024 | globenewswire.com

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 5, 2024 | benzinga.com

Preview: InspireMD's Earnings

February 28, 2024 | globenewswire.com

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

February 21, 2024 | ca.finance.yahoo.com

NSPR Mar 2024 7.500 call

February 1, 2024 | msn.com

InspireMD Announces CE Mark Recertification Under MDR

February 1, 2024 | msn.com

InspireMD Secures CE Mark Recertification Under New EU Standards

January 23, 2024 | finance.yahoo.com

We're Hopeful That InspireMD (NASDAQ:NSPR) Will Use Its Cash Wisely

November 27, 2023 | msn.com

InspireMD (NSPR) Price Target Increased by 11.49% to 4.95

November 23, 2023 | msn.com

Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround

November 6, 2023 | markets.businessinsider.com

InspireMD earnings: here's what Wall Street expects

November 6, 2023 | msn.com

InspireMD GAAP EPS of -$0.15 misses by $0.01, revenue of $1.56M beats by $0.06M

November 6, 2023 | finance.yahoo.com

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

November 3, 2023 | msn.com

InspireMD Q3 2023 Earnings Preview

November 1, 2023 | markets.businessinsider.com

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

September 25, 2023 | markets.businessinsider.com

Piper Sandler Remains a Buy on InspireMD (NSPR)

September 22, 2023 | finance.yahoo.com

InspireMD's CGuard(TM) Carotid Embolic Prevention System Featured in Live Case at Cracow Vascular Summit 2017 in Poland

August 31, 2023 | msn.com

InspireMD (NSPR) Price Target Increased by 5.45% to 4.44

August 16, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

See More Headlines

Receive NSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NYSE:NSPR
CUSIP: N/A
CIK: 1433607
Web: www.inspiremd.com
Phone: 9728887766804
Fax: N/A
Employees: 65
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.85
High Stock Price Target: $5.20
Low Stock Price Target: $4.50
Potential Upside/Downside: +132.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,920,000.00
Net Margins: -320.97%
Pretax Margin: -319.92%
Return on Equity: -55.71%
Return on Assets: -46.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.34
Quick Ratio: 6.99

Sales & Book Value

Annual Sales: $6.20 million
Price / Sales: 7.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.83 per share
Price / Book: 1.14

Miscellaneous

Outstanding Shares: 23,460,000
Free Float: 18,386,000
Market Cap: $49.03 million
Optionable: Optionable
Beta: 0.83

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Marvin L. Slosman (Age 60)
President, CEO & Director
Comp: $696.81k
Mr. Craig Shore (Age 63)
CFO, Chief Administrative Officer, Secretary & Treasurer
Comp: $625.24k
Mr. Andrea Tommasoli (Age 52)
Chief Operating Officer
Comp: $359.27k
Mr. Amir Kohen
Vice President of Finance & Human Resources
Mr. Shane Thomas Gleason (Age 49)
Chief Commercial Officer
Dr. Patrick A. Verta DVM (Age 66)
M.D., MS Stat, Executive Vice President of Clinical & Medical Affairs
Mr. Pete Ligotti
Executive VP & GM of North America
Dr. Sol J. Barer Ph.D. (Age 77)
Special Advisor to the Board
Comp: $13.92k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NSPR Stock Analysis - Frequently Asked Questions

Should I buy or sell InspireMD stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InspireMD in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NSPR shares.
View NSPR analyst ratings or view top-rated stocks.
What is InspireMD's stock price target for 2024?: 1 Wall Street analysts have issued 12-month price objectives for InspireMD's stock. Their NSPR share price targets range from $4.50 to $5.20. On average, they predict the company's stock price to reach $4.85 in the next year. This suggests a possible upside of 132.1% from the stock's current price.
View analysts price targets for NSPR or view top-rated stocks among Wall Street analysts.
How have NSPR shares performed in 2024?: InspireMD's stock was trading at $2.81 at the start of the year. Since then, NSPR shares have decreased by 25.6% and is now trading at $2.09.
View the best growth stocks for 2024 here.
When is InspireMD's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our NSPR earnings forecast.

How were InspireMD's earnings last quarter?: InspireMD, Inc. (NYSE:NSPR) posted its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. The company earned $1.76 million during the quarter, compared to analyst estimates of $1.65 million. InspireMD had a negative net margin of 320.97% and a negative trailing twelve-month return on equity of 55.71%. During the same quarter in the prior year, the business earned ($0.60) EPS.
What other stocks do shareholders of InspireMD own?: Based on aggregate information from My MarketBeat watchlists, some companies that other InspireMD investors own include Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA), Acasti Pharma (ACST), AcelRx Pharmaceuticals (ACRX), Acorda Therapeutics (ACOR), Aurora Cannabis (ACB) and Ambev (ABEV).
How do I buy shares of InspireMD?: Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NSPR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

InspireMD (NSPR) Stock Price, News & Analysis

InspireMD MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About InspireMD Stock (NYSE:NSPR)

NSPR Stock Price History

NSPR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NSPR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™